Ciclosporin ophthalmic - Santen

Drug Profile

Ciclosporin ophthalmic - Santen

Alternative Names: Cyclosporin modified ophthalmic - Santen; Cyclosporin ophthalmic - Santen; DE 076; PAPILOCK Mini ophthalmic solution 0.1%; Sanciclo

Latest Information Update: 10 Feb 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Cytokine inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Seasonal allergic rhinitis

Highest Development Phases

  • Marketed Seasonal allergic rhinitis

Most Recent Events

  • 23 Jan 2006 First global launch of ciclosporin ophthalmic
  • 23 Jan 2006 Launched for Seasonal allergic rhinitis in Japan (Ophthalmic)
  • 11 Oct 2005 Registered for Seasonal allergic rhinitis in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top